AACR 2024

Apr 10, 2024

Glioblastoma or Glioblastoma Multiforme (GBM) represents the most common primary tumor of the central nervous system (CNS). Despite advancements in diagnostic approaches and the development of new therapies, the prognosis for glioblastoma patients remains notably poor, with limited improvement observed. At AACR ...

Apr 10, 2024

The findings presented at the 2024 AACR conference revealed that among patients diagnosed with PIK3Ca-mutated MSS mCRC (n = 22), three patients attained a partial response (PR). Additionally, one more patient with PIK3Ca-mutated mCRC maintained stable disease (SD). The study successfully achieved its primary endpoi...

Apr 10, 2024

Melanoma, a type of skin cancer, poses a significant health concern globally. Advanced and metastatic stages of melanoma present particularly formidable challenges, often necessitating innovative treatment approaches to address their aggressive nature and high mortality rates. Patients with ICI-resistant metasta...

Apr 10, 2024

TG4050 is a neoantigenic cancer vaccine derived from Transgene's myvac platform and leverages NEC's Artificial Intelligence (AI) technologies to identify and predict the most potent neoantigens for immunogenicity. According to the data presented at the AACR 2024 conference, at a median follow-up duration of 18.6 mo...

Apr 10, 2024

The presentation by ALX Oncology at the AACR Annual Meeting 2024 provided promising insights into the efficacy and safety of their investigational drug, evorpacept, in combination with standard rituximab and lenalidomide for patients with relapsed or refractory B cell non-Hodgkin lymphoma (R/R B-NHL). The Phase ...

Apr 10, 2024

As per the data presented at the AACR 2024 conference, of the 21 patients who received AZD1390 in conjunction with radiation therapy at manageable doses, the median overall survival (OS) stood at 12.7 months. In arm A, comprising 75 patients with recurrent glioblastoma, the combination therapy of AZD1390 and IMR...

Apr 10, 2024

According to the data presented at the AACR 2024 conference, as of the data cutoff date of June 12, 2023, a total of 8 patients at a median age of 11 years diagnosed with inflammatory myofibroblastic tumor (n=2), high-grade glioma (n=3), renal cell carcinoma (n=2), and anaplastic large cell lymphoma (n=1, protocol ...

Apr 10, 2024

Glutathione S‑transferase Pi (GSTP) has a role in detoxification and anti‑oxidative damage response. Additionally, GSTP has a chaperone function that regulates key oncogenic pathways such as the KRAS and JNK. Since redundant pathways could compensate for the inhibition of a single kinase, targeting multiple pathway...

Apr 09, 2024

Adagrasib is an irreversible KRAS G12C inhibitor that is designed to have a 23-hour half-life, dose-dependent pharmacokinetics, and central nervous system penetration. The pooled analysis of Phase I/II (KRYSTAL-1) trial that was presented during the AACR 2024 conference demonstrated that, as of the data cutoff date...

Apr 09, 2024

Renal cell carcinoma (RCC) is the most common type of kidney cancer, characterized by various subtypes like clear cell, papillary, chromophore, and collecting duct carcinomas. Clear cell carcinoma, constituting 80% of all RCC cases commands the majority of treatment focus due to its predominance. Currently, the ...